Literature DB >> 6726217

Suppression of REM rebound by Pergolide.

J J Askenasy, M D Yahr.   

Abstract

A 71 year old retired printer developed idiopathic Parkinson's disease over a period of 3 years. On account of his worsening condition he was admitted to hospital. Following the interruption of his medication the patient developed an akinetic crisis. A 48 hour polysomnogram recording, repeated five times during hospitalization, showed severe sleep deprivation. Treatment with Pergolide alone was then started; and sleep monitoring showed suppression of REM rebound, REM only appearing when the dose of the drug was reduced. It is suggested that REM rebound phenomena produced by sleep deprivation in a Parkinson's disease patient are suppressed by the effect of the dopaminergic agent Pergolide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6726217     DOI: 10.1007/BF01255413

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  17 in total

1.  Double-blind controlled study of L-Dopa therapy in schizophrenia.

Authors:  K Inanaga; Y Nakazawa; K Inoue; H Tachibana; M Oshima
Journal:  Folia Psychiatr Neurol Jpn       Date:  1975

2.  The effect of dream deprivation.

Authors:  W DEMENT
Journal:  Science       Date:  1960-06-10       Impact factor: 47.728

3.  Effects of bromocriptine on central dopaminergic receptors.

Authors:  M Trabucchi; P F Spano; G C Tonon; L Frattola
Journal:  Life Sci       Date:  1976-07-15       Impact factor: 5.037

4.  Lergotrile and lisuride: in vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptor.

Authors:  J W Kebabian; P R Kebabian
Journal:  Life Sci       Date:  1978-11-27       Impact factor: 5.037

5.  The behavioral effects of amphetamine on REM deprived rats.

Authors:  J Ferguson; W Dement
Journal:  J Psychiatr Res       Date:  1969-12       Impact factor: 4.791

6.  Unexpected findings with apomorphine and their possible consequences.

Authors:  G C Cotzias; I Mena; P S Papavasiliou; J Mendez
Journal:  Adv Neurol       Date:  1974

7.  Effects of levodopa in Parkinsonian patients with dementia.

Authors:  O W Sacks; M S Kohl; C R Messeloff; W F Schwartz
Journal:  Neurology       Date:  1972-05       Impact factor: 9.910

Review 8.  Levodopa.

Authors:  M D Yahr
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

9.  Overview of present day treatment of Parkinson's disease.

Authors:  M D Yahr
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

10.  Dopamine metabolism and receptor sensitivity in rat brain after REM sleep deprivation.

Authors:  J Farber; J D Miller; K A Crawford; B A McMillen
Journal:  Pharmacol Biochem Behav       Date:  1983-04       Impact factor: 3.533

View more
  3 in total

1.  Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Are periodic movements in sleep a basal ganglia dysfunction?

Authors:  J J Askenasy; E D Weitzman; M D Yahr
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study.

Authors:  Fabio Placidi; Francesca Izzi; Andrea Romigi; Paolo Stanzione; Maria Grazia Marciani; Livia Brusa; Francesca Sperli; Salvatore Galati; Patrizio Pasqualetti; Mariangela Pierantozzi
Journal:  J Neurol       Date:  2008-06-02       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.